Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis

被引：5

作者：

Abdallah, Nadine ^{[1
]}

Sidana, Surbhi ^{[1
,2
]}

Dispenzieri, Angela ^{[1
]}

Lacy, Martha ^{[1
]}

Buadi, Francis ^{[1
]}

Hayman, Suzanne ^{[1
]}

Kapoor, Prashant ^{[1
]}

Leung, Nelson ^{[1
,3
]}

Dingli, David ^{[1
]}

Hwa, Yi Lisa ^{[1
]}

Lust, John ^{[1
]}

Russell, Stephen ^{[1
]}

Gonsalves, Wilson ^{[1
]}

Go, Ronald ^{[1
]}

Hogan, William ^{[1
]}

Kyle, Robert ^{[1
]}

Rajkumar, S. Vincent ^{[1
]}

Gertz, Morie ^{[1
]}

Kumar, Shaji ^{[1
]}

机构：

[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN 55905 USA

[2] Stanford Univ, Dept Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA

[3] Mayo Clin, Dept Internal Med, Div Nephrol, Rochester, MN USA

来源：

BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / 07期

关键词：

MELPHALAN PLUS DEXAMETHASONE; HIGH-DOSE MELPHALAN; MULTIPLE-MYELOMA; RESCUE TREATMENT; STAGING SYSTEM; BORTEZOMIB; THERAPY; CYCLOPHOSPHAMIDE; LENALIDOMIDE; POMALIDOMIDE;

D O I：

10.1038/s41409-020-0964-8

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

In the presence of effective treatment options for systemic light chain (AL) amyloidosis, autologous stem cell transplantation (ASCT) is sometimes deferred after stem cell collection. We designed this retrospective study to compare overall survival (OS) between patients who proceed directly to ASCT after stem cell collection and those who defer ASCT. We included patients with AL amyloidosis who had stem cell collection at Mayo Clinic, Minnesota, from 2004 to 2018. ASCT was considered "early" if performed within 90 days of collection, and "deferred" if performed after 90 days, or not done by last follow up. We included 651 patients; 527 underwent early ASCT and 124 deferred ASCT. There was no difference in OS with early vs. deferred ASCT (median OS: 13.0 vs. 11.4 years, respectively,P = 0.28). There was no difference in OS between the 2 groups among patients with early or advanced Mayo Stage. Among patients who achieved >= very good partial response at the time of collection, OS in the early and deferred groups was 14.2 and 13.4 years, respectively (P = 0.06). Survival outcomes are similar with early and deferred ASCT. Further studies are needed to identify patients who would benefit from each approach.

引用

页码：1297 / 1304

页数：8

共 31 条

[1] Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation [J].

Afrough, Aimaz ;

Saliba, Rima M. ;

Hamdi, Amir ;

Honhar, Medhavi ;

Varma, Ankur ;

Cornelison, A. Megan ;

Rondon, Gabriela ;

Parmar, Simrit ;

Shah, Nina D. ;

Bashir, Qaiser ;

Hosing, Chitra ;

Popat, Uday ;

Weber, Donna M. ;

Thomas, Sheeba ;

Orlowski, Robert Z. ;

Champlin, Richard E. ;

Qazilbash, Muzaffar H. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (11) :2197-2203

[2]

[Anonymous], 1989, VERS 10

[3] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Hulin, Cyrille ;

Leleu, Xavier ;

Caillot, Denis ;

Escoffre, Martine ;

Arnulf, Bertrand ;

Macro, Margaret ;

Belhadj, Karim ;

Garderet, Laurent ;

Roussel, Murielle ;

Payen, Catherine ;

Mathiot, Claire ;

Fermand, Jean P. ;

Meuleman, Nathalie ;

Rollet, Sandrine ;

Maglio, Michelle E. ;

Zeytoonjian, Andrea A. ;

Weller, Edie A. ;

Munshi, Nikhil ;

Anderson, Kenneth C. ;

Richardson, Paul G. ;

Facon, Thierry ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc ;

Moreau, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) :1311-1320

[4] High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].

Child, JA ;

Morgan, GJ ;

Davies, FE ;

Owen, RG ;

Bell, SE ;

Hawkins, K ;

Brown, J ;

Drayson, MT ;

Selby, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883

[5] Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study [J].

D'Souza, Anita ;

Dispenzieri, Angela ;

Wirk, Baldeep ;

Zhang, Mei-Jie ;

Huang, Jiaxing ;

Gertz, Morie A. ;

Kyle, Robert A. ;

Kumar, Shaji ;

Comenzo, Raymond L. ;

Gale, Robert Peter ;

Lazarus, Hillard M. ;

Savani, Bipin N. ;

Cornell, Robert F. ;

Weiss, Brendan M. ;

Vogl, Dan T. ;

Freytes, Cesar O. ;

Scott, Emma C. ;

Landau, Heather J. ;

Moreb, Jan S. ;

Costa, Luciano J. ;

Ramanathan, Muthalagu ;

Callander, Natalie S. ;

Kamble, Rammurti T. ;

Olsson, Richard F. ;

Ganguly, Siddhartha ;

Nishihori, Taiga ;

Kindwall-Keller, Tamila L. ;

Wood, William A. ;

Mark, Tomer M. ;

Hari, Parameswaran .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) :3741-+

[6] Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis [J].

Dispenzieri, A ;

Gertz, MA ;

Kyle, RA ;

Lacy, MQ ;

Burritt, MF ;

Therneau, TM ;

Greipp, PR ;

Witzig, TE ;

Lust, JA ;

Rajkumar, SV ;

Fonseca, R ;

Zeldenrust, SR ;

McGregor, CGA ;

Jaffe, AS .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) :3751-3757

[7] The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis [J].

Dispenzieri, Angela ;

Lacy, Martha Q. ;

Zeldenrust, Steven R. ;

Hayman, Suzanne R. ;

Kumar, Shaji K. ;

Geyer, Susan M. ;

Lust, John A. ;

Allred, Jacob B. ;

Witzig, Thomas E. ;

Rajkumar, S. Vincent ;

Greipp, Philip R. ;

Russell, Stephen J. ;

Kabat, Brian ;

Gertz, Morie A. .

BLOOD, 2007, 109 (02) :465-470

[8] Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement [J].

Dispenzieri, Angela ;

Buadi, Francis ;

Kumar, Shaji K. ;

Reeder, Craig B. ;

Sher, Tamur ;

Lacy, Martha Q. ;

Kyle, Robert A. ;

Mikhael, Joseph R. ;

Roy, Vivek ;

Leung, Nelson ;

Grogan, Martha ;

Kapoor, Prashant ;

Lust, John A. ;

Dingli, David ;

Go, Ronald S. ;

Hwa, Yi Lisa ;

Hayman, Suzanne R. ;

Fonseca, Rafael ;

Ailawadhi, Sikander ;

Bergsagel, P. Leif ;

Chanan-Khan, Ascher ;

Rajkumar, S. Vincent ;

Russell, Stephen J. ;

Stewart, Keith ;

Zeldenrust, Steven R. ;

Gertz, Morie A. .

MAYO CLINIC PROCEEDINGS, 2015, 90 (08) :1054-1081

[9] Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma [J].

Dunavin, Neil C. ;

Wei, Lai ;

Elder, Patrick ;

Phillips, Gary S. ;

Benson, Don M., Jr. ;

Hofmeister, Craig C. ;

Penza, Sam ;

Eld, Carli Greenfi ;

Rose, Karen S. ;

Rieser, Gisele ;

Merritt, Lisa ;

Ketcham, Jill ;

Heerema, Nyla ;

Byrd, John C. ;

Devine, Steven M. ;

Efebera, Yvonne A. .

LEUKEMIA & LYMPHOMA, 2013, 54 (08) :1658-1664

[10] High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial [J].

Fermand, JP ;

Ravaud, P ;

Chevret, S ;

Divine, M ;

Leblond, V ;

Belanger, C ;

Macro, M ;

Pertuiset, E ;

Dreyfus, F ;

Mariette, X ;

Boccacio, C ;

Brouet, JC .

BLOOD, 1998, 92 (09) :3131-3136

← 1 2 3 4 →